Search

Displaying results 11 - 20 of 28 in total
  1. Indication

    Recurrent mismatch repair proficient (pMMR) endometrial cancer

    go.drugbank.com/conditions/DBCOND0168678
    Drugs: Durvalumab
  2. Indication

    Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)

    go.drugbank.com/conditions/DBCOND0127684
    Drugs: Durvalumab
  3. Indication

    Advanced, primary Endometrial Cancer

    go.drugbank.com/conditions/DBCOND0168675
    Drugs: Dostarlimab · Durvalumab
  4. Indication

    Recurrent Endometrial Cancer

    go.drugbank.com/conditions/DBCOND0054384
    Drugs: Dostarlimab · Durvalumab
  5. Indication

    Advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer

    go.drugbank.com/conditions/DBCOND0138846
    Drugs: Dostarlimab · Durvalumab
  6. Indication

    Recurrent Mismatch Repair-deficient (dMMR) Endometrial Cancer

    go.drugbank.com/conditions/DBCOND0138845
    Drugs: Dostarlimab · Durvalumab
  7. Indication

    Advanced Hepatocellular Carcinoma (HCC)

    go.drugbank.com/conditions/DBCOND0046987
    Drugs: Durvalumab · Ipilimumab · Nivolumab
  8. Indication

    Metastatic Biliary Tract Cancer

    go.drugbank.com/conditions/DBCOND0046438
    Drugs: Durvalumab · Pembrolizumab · Zanidatamab
  9. Drug

    Imdusiran

    go.drugbank.com/drugs/DB19014
    Investigational

    Imdusiran is under investigation in clinical trial NCT06245291 (Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection).

  10. Drug

    Ociperlimab

    go.drugbank.com/drugs/DB18947
    Investigational

    Ociperlimab is under investigation in clinical trial NCT04866017 (A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (Ccrt) in Patients With Stage